Section 3-3 requires representatives to recognise their social responsibility and to make sustained efforts to acquire the necessary professional knowledge and to cultivate their ethical grounding. Where the other provisions in Chapter 3 impose external constraints—things that must or must not be done—this section targets the representative's internal capacities: the level of knowledge and ethical awareness they bring to every interaction.

What this provision is really asking: Knowing the GL is necessary but not sufficient. Accurate, high-quality information provision—of the kind the GL demands—requires the scientific fluency to understand pharmaceutical data in depth, and the ethical commitment to put the patient's interests first. Neither is a one-time achievement.

01Recognising social responsibility — what it means to be a representative

Representatives—MRs, MSLs, and their equivalents—hold a role in the social machinery of appropriate medicine use. The information they provide shapes prescribing decisions; those decisions shape treatment outcomes; those outcomes affect patients. Recognising this chain is the practical content of "recognising social responsibility."

Understanding oneself as a professional communicator of medical information—not merely a sales operative—is also the foundation for self-development motivation. Insufficient knowledge directly creates a risk of conveying incorrect information, with consequences for patient safety. Feeling the weight of that responsibility is what drives sustained learning.

So what: The GL makes social responsibility explicit in order to place representatives within the healthcare system—not outside it. Without that self-recognition, knowledge gaps and ethical carelessness are more likely to go unnoticed and uncorrected.

So why: A representative who lacks professional self-awareness tends to deflect accountability: "the company instructed me," "the material said so." Anchoring obligations in individual self-awareness breaks that pattern of externally attributed responsibility, and confirms that each representative is an autonomous, reasoning agent.

02Acquiring the necessary knowledge — what, and to what standard

The knowledge a representative must maintain falls into three broad domains. First, product knowledge: pharmacology, pharmacokinetics, clinical trial data, and the safety profile of the products they represent. Second, disease-area knowledge: pathophysiology, diagnostic criteria, standard-of-care treatment, and the relevant clinical guidelines. Third, regulatory and ethical knowledge: the GL itself, the Pharmaceutical and Medical Device Act, the appropriate advertising standards, and related frameworks.

"Acquiring" means more than passing a one-time examination. Scientific understanding evolves; guidelines are revised. As long as a representative is active, they are obliged to keep their knowledge current. When a product's prescribing information is updated, new safety data emerge, or published evidence shifts, the representative must update their understanding accordingly.

So what: A representative who allows their knowledge to become outdated and then communicates on that basis is directly at odds with the GL's requirement for information "grounded in scientific and objective evidence." Stale knowledge is a mechanism for unintentional misinformation.

So why: Without continuous knowledge updates, a representative may fail to communicate new safety signals accurately, may be unable to respond correctly to a physician's clinical question, and increases the probability of providing a misleading explanation. Ongoing knowledge development is the infrastructure that makes GL compliance possible in practice.

03Cultivating ethical awareness — why the information is being provided

"Cultivating ethical awareness" stands alongside knowledge acquisition as the second pillar of professional self-development. Ethical awareness means an internalised commitment to placing the patient's interests first, to being honest with healthcare professionals, and to prioritising appropriate use of medicines over short-term sales objectives.

Without ethical awareness, knowledge is at risk of being misdirected. A representative who is thoroughly familiar with a product's adverse-event profile but downplays those risks in order to encourage prescribing is misusing knowledge in a way that directly harms patients. Possessing knowledge and applying it in the patient's interest are two different things.

So what: Cultivating ethical awareness is not abstract moral education. It is a practical, ongoing development of the habit of asking how one's own actions affect patients—and letting the answer guide behaviour.

So why: Providing pharmaceutical information is simultaneously a commercial activity and an act that serves a public health function. Knowledge without ethics can become a tool for harm. The GL explicitly includes ethical cultivation to prevent representatives from operating solely on commercial logic—"the goal is to sell"—and to instil the medical logic: "the goal is to ensure that accurate information reaches the patient."

04Self-development as an ongoing obligation

Section 3-3 uses the phrase "make efforts," which means it does not set a specific measurable standard for knowledge or ethical attainment. This is not a licence to treat the requirement as satisfied by good intentions alone. The substantive meaning of an ongoing obligation is to sustain a pattern of parallel-to-work learning and reflection throughout one's career.

Active participation in MR certification programmes, in-house medical education sessions, and scientific update seminars constitutes fulfilment of this obligation. Conversely, completing certification and then performing no further learning—still communicating on the basis of knowledge that is several years old—cannot reasonably be described as making the required effort.

So what: An ongoing effort obligation cannot be satisfied by appearances. What matters is whether the representative's knowledge and ethical grounding are actually reflected in the quality of their work. The company carries responsibility for creating the conditions for self-development; the representative carries responsibility for using them.

So why: In a field where regulations, science, and the treatment landscape all change continuously, representatives who operate on static knowledge carry a structural risk. Framing this as a personal ongoing obligation—rather than purely a corporate training matter—formally affirms that each representative's continuous growth is itself a professional norm, not an optional extra.